Drugs / Detox-B adjuvant
last change Jan 1996 re-read 2 minutes ago

Detox-B adjuvant

Developed for
cutaneous melanoma
Investigated by
GlaxoSmithKline

Trials 1 · a red edge is where a trial was stopped

19961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT00002767 Jan 1996 → ? cutaneous melanoma GlaxoSmithKline Unknown No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Detox-B adjuvant ClinicalTrials.gov intervention name — accepted as the source's own label NCT00002767
Route Subcutaneous “allogenic melanoma cell lysate vaccine with detoxified endotoxin subcutaneously (SQ)” NCT00002767